Jane Street
AKBA icon

Jane Street’s Akebia Therapeutics AKBA Stock Holding History

Jane Street’s Portfolio AKBA Stock Details AKBA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$17.7K Buy
+15,500
New +$18.5K ﹤0.01% 11238
2025
Q2 		– Sell
-15,300
Closed -$29.4K – 9522
2025
Q1 		$29.4K Buy
+15,300
New +$31.2K ﹤0.01% 9098
2024
Q2 		– Sell
-24,000
Closed -$43.9K – 9262
2024
Q1 		$43.9K Buy
+24,000
New +$38.4K ﹤0.01% 8768
2022
Q2 		– Sell
-157,700
Closed -$113K – 9554
2022
Q1 		$113K Buy
157,700
+128,800
+446% +$276K ﹤0.01% 9394
2021
Q4 		$65K Sell
28,900
-8,400
-23% -$22.9K ﹤0.01% 9427
2021
Q3 		$107K Buy
37,300
+300
+0.8% +$857 ﹤0.01% 9260
2021
Q2 		$140K Buy
37,000
+22,300
+152% +$75.1K ﹤0.01% 9089
2021
Q1 		$50K Sell
14,700
-9,400
-39% -$33.9K ﹤0.01% 8838
2020
Q4 		$67K Buy
+24,100
New +$70.4K ﹤0.01% 7287

Other funds holding AKBA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Jane Street's AKBA Position: Q2 2026 in Review

Jane Street sold out of Akebia Therapeutics (AKBA) in Q2 2026, closing a stake of 1,456,674 shares — an estimated $1.73M sold.

Jane Street first reported a position in AKBA in Q2 2014 and held it in 33 quarters. The position peaked at $2.02M in Q1 2026. 171 funds tracked by Wall St. Rank hold AKBA as of Q2 2026.

  • Jane Street reported no remaining Akebia Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Jane Street sold 1,456,674 Akebia Therapeutics shares in Q2 2026, an estimated $1.73M.
  • Jane Street first reported a position in Akebia Therapeutics in Q2 2014 and held it in 33 quarters.
  • Jane Street's Akebia Therapeutics position peaked at $2.02M in Q1 2026.
  • 171 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q2 2026.

Based on Jane Street's 13F filing for Q2 2026, filed 14 Aug 2026.